Psoriatic Arthritis News
- EULAR 2023 HIIT Has Sustainable Effects in Inflammatory Arthritis
- EULAR 2023 EULAR PsA Update Emphasizes Safety, Non-MSK Manifestations
- Alert EU Approves Bimekizumab for PsA and AxSpA
- Why Not Both? Dual Biologics for RA and PsA
- EULAR 2023 ILD Risk Elevated in RA, PsA After Starting DMARDs
- Alert First IL-17 Inhibitor Approved in Europe for HS Patients
- Enthesitis Linked to Dupilumab Use for Atopic Dermatitis
- Alert FDA Approves Yuflyma as Ninth Adalimumab Biosimilar
- Alert FDA Approves Autoinjector Pen for Humira Biosimilar, Cyltezo
- SPARTAN 2023 TNF, JAK Inhibitors' CV Safety Compared in PsA, AxSpA
- Alert FDA Approves Upadacitinib (Rinvoq) for Crohn's Disease
- Brepocitinib Shows Promise for Patients With PsA
- Axial SpA vs Axial PsA: Different Entities?
- BSR 2023 Meta-Analysis Probes Cancer Risk Concern for JAK Inhibitors
- NPF Provides Guidance for Virtual Psoriasis Visits
- Alert FDA Approves New Formulation of Hyrimoz Adalimumab Biosimilar
- Managing Inflammatory Rheumatism With Diet and Nutrition
- AAD 2023 Dermatology Risks Are Likely Different for JAK Inhibitors
- Biologics May Delay Arthritis in Psoriasis Patients
- Isolated Nail Psoriasis May Be Sign of Psoriatic Arthritis